Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$4.4 billion.

  • Ultragenyx Pharmaceutical's Retained Earnings fell 1516.5% to -$4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 billion, marking a year-over-year decrease of 1516.5%. This contributed to the annual value of -$4.0 billion for FY2024, which is 1680.17% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Retained Earnings is -$4.4 billion, which was down 1516.5% from -$4.2 billion recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Retained Earnings' 5-year high stood at -$1.8 billion during Q1 2021, with a 5-year trough of -$4.4 billion in Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$3.1 billion (2023), whereas its average is -$3.1 billion.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Retained Earnings plummeted by 1312.35% in 2021 and then plummeted by 3475.12% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Retained Earnings (Quarter) stood at -$2.1 billion in 2021, then tumbled by 34.12% to -$2.8 billion in 2022, then fell by 21.81% to -$3.4 billion in 2023, then decreased by 16.8% to -$4.0 billion in 2024, then dropped by 11.28% to -$4.4 billion in 2025.
  • Its last three reported values are -$4.4 billion in Q3 2025, -$4.2 billion for Q2 2025, and -$4.1 billion during Q1 2025.